NCT02418455View on ClinicalTrials.gov

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

March 26, 2019

Study Completion Date

March 26, 2019

Conditions

Sly SyndromeMPS VIIMucopolysaccharidosisMucopolysaccharidosis VII

Interventions

DRUG

UX003

solution for intravenous infusion

Trial Locations (5)

10038

New York University Langone Medical Center, New York

20010

Children's National Health System, Washington D.C.

41013

Hospital Universitario Virgen Del Rocio, Seville

84132

University of Utah Hospital, Salt Lake City

4099-345

Centro Hospitalar do Porto, Porto

All Listed Sponsors

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT02418455 - Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age | Biotech Hunter | Biotech Hunter